Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ODD +26.4%, SIG +16.1%, JILL +14.4%, INNV +13.7%, AVO +5.7%, CAL +5%, CHWY +3.7%, SUNB +3.2%, FTK +3.1% (guidance), KFY +1.7%, ASX +1.2% (Aug revs), JMKE +0.5%
Other news:
- CHYM +9.6% (to acquire Stride Bank for $590 mln in cash; also offers guidance)
- CMTG +8.4% (CEO/Chairman discloses insider purchase)
- CSR +7.5% (Independence Realty Trust and Centerspace (CSR) to merge in $8.1 billion combination)
- IRD +5.3% (reports positive Phase 1/2 OPGx-BEST1 cohort data; FDA aligns on potential pivotal endpoint)
- ASR +4.9% (reports August passenger traffic)
- INBX +4.9% (discloses insider purchases)
- ASMB +4.7% (exercises U.S. profit-share option with GILD for HSV program)
- EIKN +4.1% (10% Owner discloses insider purchase)
- SPTX +3.9% (Phase 1 driving trial met endpoints for GlyphAllo)
- WS +3.8% (signs profit transfer agreement with Kloeckner after takeover)
- AUTL +3.8% (FDA grants RMAT designation to obe-cel in lupus indications)
- CMPS +3.1% (posts 52-week Phase 3 COMP005 data for COMP360 in TRD)
- JKS +3% (proposes name change to Jinko Holdings, outlines strategic investment focus)
- CSAN +3% (confirmed last trading day of the ADSs on the NYSE will be September 18)
- RKLB +2.9% (launches germanium-free IMM Apex solar cell for space applications)
- BETR +2.3% (COO to depart)
- GENI +2.3% (launches new athlete-led sports media venture)
- MNKD +2.3% (enters Rose Pharma licensing deal for inhaled GLP-1 weight-management program)
- AVEX +2.2% (wins $20.5 mln in new one-way attack system awards)
- XNDU +2.2% (partners with ASML on lithography for photonic quantum chips)
- KROS +2.1% (authorizes new $5 mln share repurchase program)
- CAMP +1.8% (to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder)